Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases–including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.
Looking for leads, investment insights, or competitive intelligence?
News about Pfizer
Ringaskiddy residents say they have an extra spring in their step.
Insights from our annual roundtable on the best stocks and the biggest risks.
The "little blue pill" has officially become the "little white pill," and for a big discount.
The little blue pill will finally be available without a prescription.
He'll put in $50 million to start, with plans to invest at least another $50 million.